Immunology, Immunotherapy, Internal medicine, Cancer and Immune system are his primary areas of study. His study in Immunology is interdisciplinary in nature, drawing from both Cancer cell and Receptor. A large part of his Immunotherapy studies is devoted to Immune checkpoint.
He regularly ties together related areas like Oncology in his Internal medicine studies. His work deals with themes such as Clinical trial, Bioinformatics, Young adult, Gastroenterology and Hepatitis, which intersect with Cancer. Aurélien Marabelle has included themes like Immunosuppression, Monoclonal antibody and Antigen in his Immune system study.
His main research concerns Internal medicine, Oncology, Immunotherapy, Immune system and Cancer. Many of his research projects under Internal medicine are closely connected to In patient with In patient, tying the diverse disciplines of science together. His Oncology research is multidisciplinary, incorporating elements of Proportional hazards model, Disease, Neuroblastoma and Cohort.
His study explores the link between Immunotherapy and topics such as Pharmacology that cross with problems in Agonist. His Immune system study necessitates a more in-depth grasp of Immunology. His work carried out in the field of Immunology brings together such families of science as Cancer cell and Blockade.
His main research concerns Internal medicine, Oncology, Cancer, Immunotherapy and Immune system. His work in the fields of Pembrolizumab and Adverse effect overlaps with other areas such as In patient. In the field of Oncology, his study on Renal cell carcinoma overlaps with subjects such as Head and neck squamous-cell carcinoma.
The study incorporates disciplines such as Pseudoprogression, Clinical trial, Disease and Coronavirus disease 2019 in addition to Cancer. His Immunotherapy research is multidisciplinary, incorporating perspectives in Targeted therapy and Medical physics. Immunology covers Aurélien Marabelle research in Immune system.
Aurélien Marabelle mainly focuses on Internal medicine, Oncology, Immune system, Cancer and Immunotherapy. His Internal medicine study integrates concerns from other disciplines, such as Imaging biomarker and Melanoma, Cutaneous melanoma. His Oncology research integrates issues from Immune checkpoint, Clinical trial, Immunosenescence, CTLA-4 and Tumor antigen.
His Immune system study also includes fields such as
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
J.M. Michot;C. Bigenwald;S. Champiat;M. Collins.
European Journal of Cancer (2016)
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.
Stephane Champiat;Stephane Champiat;Laurent Dercle;Samy Ammari;Christophe Massard.
Clinical Cancer Research (2017)
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
S. Champiat;S. Champiat;O. Lambotte;E. Barreau;R. Belkhir.
Annals of Oncology (2016)
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
Celine Boutros;Ahmad Tarhini;Emilie Routier;Olivier Lambotte.
Nature Reviews Clinical Oncology (2016)
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
Roger Sun;Roger Sun;Elaine Johanna Limkin;Elaine Johanna Limkin;Maria Vakalopoulou;Maria Vakalopoulou;Laurent Dercle;Laurent Dercle.
Lancet Oncology (2018)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle;Dung T. Le;Paolo A. Ascierto;Anna Maria Di Giacomo.
Journal of Clinical Oncology (2020)
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Aurélien Marabelle;Holbrook Kohrt;Idit Sagiv-Barfi;Bahareh Ajami.
Journal of Clinical Investigation (2013)
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy
J.M. Pitt;A. Marabelle;A. Marabelle;A. Eggermont;J.-C. Soria.
Annals of Oncology (2016)
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E. Kohrt;Ariane Thielens;Aurelien Marabelle;Aurelien Marabelle;Idit Sagiv-Barfi.
Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report.
Jean-Marie Michot;Laurence Albiges;Nathalie Chaput;Veronique Saada.
Annals of Oncology (2020)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: